En undersøgelse, der skal give børn og unge, der har gennemført kliniske undersøgelser, der involverer Gilead-hiv-behandlinger, fortsat adgang til undersøgelse af stof
Et åbent, enkeltarmsstudie for at give deltagere, der har gennemført pædiatriske kliniske undersøgelser, der involverer Gilead-hiv-behandling, fortsat adgang til lægemiddel
The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.
The primary objectives of this study are as follows:
- To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.
- To evaluate the safety of the study drug(s) in participants with HIV-1.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Medicin: F/TAF (High Dose Tablet)
- Medicin: F/TAF (Low Dose Tablet)
- Medicin: F/TAF (Lowest Dose Tablet)
- Medicin: B/F/TAF (High Dose)
- Medicin: B/F/TAF (Low Dose)
- Medicin: B/F/TAF (High Dose TOS)
- Medicin: 3rd ARV Agent
- Medicin: E/C/F/TAF
- Medicin: E/C/F/TAF (Low Dose)
- Medicin: F/TAF (High Dose TOS)
- Medicin: F/TAF (Low Dose TOS)
- Medicin: F/TAF (Lowest Dose TOS)
- Medicin: Cobicistat (High Dose)
- Medicin: Cobicistat (Low Dose)
- Medicin: Cobicistat (TOS)
- Medicin: B/F/TAF (Low Dose TOS)
- Medicin: B/F/TAF (Lowest Dose TOS)
- Medicin: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
- Medicin: ATV
- Medicin: DRV
- Medicin: Lopinavir Boosted with ritonavir (LPV/r)
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Gilead Clinical Study Information Center
- Telefonnummer: 1-833-445-3230 (GILEAD-0)
- E-mail: GileadClinicalTrials@gilead.com
Studiesteder
-
-
-
Buenos Aires, Argentina, C1141 ACG
- Afsluttet
- Helios Salud
-
-
-
-
-
Panama City, Panama, 0816-00383
- Afsluttet
- Hospital del Niño
-
-
-
-
-
Cape Town, Sydafrika, 7505
- Rekruttering
- University of Stellenbosch
-
Durban, Sydafrika, 3629
- Rekruttering
- Enhancing Care Foundation
-
Johannesburg, Sydafrika, 2112
- Rekruttering
- Rahima Moosa Mother and Child Hospital
-
Johannesburg, Sydafrika, 2038
- Rekruttering
- WITS RHI Research Centre
-
Paarl, Sydafrika, 7626
- Rekruttering
- Be Part Yoluntu Centre
-
Pretoria, Sydafrika, 0087
- Rekruttering
- The Aurun Institute
-
Soweto, Sydafrika, 2013
- Rekruttering
- Perinatal HIV Research Unit
-
-
-
-
-
Bangkok Noi, Thailand, 10700
- Aktiv, ikke rekrutterende
- Faculty of Medicine - Mahidol University
-
Khon Kaen, Thailand, 40002
- Aktiv, ikke rekrutterende
- Khon Kaen University
-
-
-
-
-
Kampala, Uganda, 10005
- Rekruttering
- Joint Clinical Research Centre
-
Kampala, Uganda, 256
- Rekruttering
- MU-JHU Research Collaboration/MU-JHU Care Ltd
-
Kampala, Uganda
- Rekruttering
- Baylor College of Medicine
-
Kampala, Uganda
- Rekruttering
- Strengthening Institutional Capacity for Research Administration (SICRA)
-
Masaka, Uganda
- Rekruttering
- Africa Medical and Behavioral Sciences Organisation
-
-
-
-
-
Harare, Zimbabwe
- Rekruttering
- University of Zimbabwe Clinical Research Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Completed an applicable parent study: GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, or GS-US-216-0128, and gave consent to study participation.
Key Exclusion Criteria:
-
Individuals planning to switch to B/F/TAF on Day 1 with plasma HIV RNA ≥ 50 copies/mL during the last parent study visit prior to screening/Day 1 visit.
- Note: individuals planning to switch after Day 1 must not have plasma HIV RNA ≥ 50 copies/mL (or detectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
-
Individuals planning to switch to B/F/TAF with any ongoing Grade 3 or 4 drug-related AE or clinically relevant Grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of B/F/TAF prior to treatment switch.
-
For those on B/F/TAF or planning to switch to B/F/TAF: previous treatment discontinuation of any component of B/F/TAF due to toxicity or intolerance.
-
For those planning to switch to B/F/TAF: known hypersensitivity to any component of the study drug, its metabolites, or formulation excipients.
-
Ongoing treatment with or prior use of any prohibited medications.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Rollover from Parent Study: GS-US-311-1269: Parent Study Drug (F/TAF) or B/F/TAF
Participants will continue to take the study drug they were taking in the parent study, emtricitabine/tenofovir alafenamide (F/TAF) along with a 3rd antiretroviral (ARV) agent. The dose of F/TAF will be based on the weight of the participant, ranging between 120/15 mg to 200/25 mg. The dose of F/TAF will be different when given with the boosted and the unboosted 3rd ARV agent: F/TAF (High Dose Tablet) for unboosted 3rd ARV agent; F/TAF (Low Dose Tablet) for the boosted 3rd ARV agent. Participants may switch to B/F/TAF, at a dose based on participant's weight. |
200/25 mg fixed-dose combination (FDC) tablet administered orally
Andre navne:
200/10 mg FDC tablet administered orally 120/15 mg FDC tablet administered orally 50/200/25 mg FDC tablet administered orally
Andre navne:
30/120/15 mg FDC tablet administered orally
Andre navne:
15/60/7.52 mg TOS administered orally
Andre navne:
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country |
|
Eksperimentel: Rollover from Parent Study: GS-US-292-0106: Parent Study Drug (E/C/F/TAF) or B/F/TAF
Participants will continue to take the study drug they were taking in the parent study, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The dose of E/C/F/TAF will be based on the weight of the participant, ranging between 90/90/120/6 mg to 150/150/200/10 mg. Participants may switch to B/F/TAF at a dose based on participant's weight. |
50/200/25 mg FDC tablet administered orally
Andre navne:
30/120/15 mg FDC tablet administered orally
Andre navne:
150/150/200/10 mg tablet administered orally
Andre navne:
90/90/120/6 mg tablet administered orally |
|
Eksperimentel: Rollover Parent Study GS-US-216-0128: Parent Study Drug (Combination Drugs) or B/F/TAF
Participants will continue to take the following study drugs they were taking in the parent study:
The dose of F/TAF will be based on the weight of the participant, ranging between 15/1.88 mg and 200/25 mg, once daily. Additionally, the dose of COBI will be based on the weight of the participant, ranging between 30 mg and 150 mg, once or twice daily. Participants may switch to B/F/TAF at a dose based on participant's weight. |
200/25 mg fixed-dose combination (FDC) tablet administered orally
Andre navne:
120/15 mg FDC tablet administered orally 50/200/25 mg FDC tablet administered orally
Andre navne:
30/120/15 mg FDC tablet administered orally
Andre navne:
15/60/7.52 mg TOS administered orally
Andre navne:
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country 60/7.5 mg tablet for oral suspension (TOS) administered orally 30/3.75 mg TOS administered orally 15/1.88 mg TOS administered orally 150 mg tablet administered orally
Andre navne:
90 mg tablet administered orally
Andre navne:
30 mg TOS administered orally
Andre navne:
7.5/30/3.76 mg TOS administered orally
Andre navne:
3.76/15/1.88 mg TOS administered orally
Andre navne:
NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC) Administered according to the prescribing information Administered according to the prescribing information Administered according to the prescribing information |
|
Eksperimentel: Rollover from Parent Studies: GS-US-380-1474 and CO-US-380-5578: Parent Study Drug (B/F/TAF)
Participants will continue to take the study drug they were taking in the parent study, B/F/TAF. Participants who are diagnosed with HIV-1 infection in parent study CO-US-380-5578 and complete the study drug will continue to take the study drug they were taking in the parent study, B/F/TAF. The dose of B/F/TAF will be based on the weight of the participant. |
50/200/25 mg FDC tablet administered orally
Andre navne:
30/120/15 mg FDC tablet administered orally
Andre navne:
15/60/7.52 mg TOS administered orally
Andre navne:
7.5/30/3.76 mg TOS administered orally
Andre navne:
3.76/15/1.88 mg TOS administered orally
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study
Tidsramme: Up to 2.8 Years
|
Up to 2.8 Years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentdel af deltagere, der oplever behandlingsfremkaldte bivirkninger (TEAE'er)
Tidsramme: Op til 9,5 år
|
Op til 9,5 år
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Gilead Study Director, Gilead Sciences
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Farmaceutiske præparater
- Doseringsformer
- Thiazoler
- Azoler
- Nukleinsyrer, nukleotider og nukleosider
- Syrer, acyklisk
- Carboxylsyrer
- Puriner
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Organophosphorforbindelser
- Nukleosider
- Deoxyribonucleosider
- Organophosphonater
- Adenin
- Lægemiddelkombinationer
- Tenofovir
- Emtricitabin
- Carbamater
- Cobicistat
- Elvitegravir, Cobicistat, Emtricitabin, Tenofovir Disoproxil Fumarate Lægemiddelkombination
- Ritonavir
- Tabletter
- Bictegravir, emtricitabin, tenofovir alafenamid, lægemiddelkombination
- emtricitabin tenofovir alafenamid
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GS-US-380-6684
- 2024-000521-40 (Anden identifikator: European Medicines Agency)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .